Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217104 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Letters, 2024. Verfasst von Nan Yan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Neoplasm, Residual, High-Throughput Nucleotide Sequencing, Flow Cytometry, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, NIHR Oxford Biomedical Research Centre.
Abstract (Originalsprache)
Results of measurable residual disease (MRD)-testing by next-generation sequencing (NGS) correlate with relapse risk in adults with B-cell acute lymphoblastic leukemia (ALL) receiving chemotherapy or an allotransplant from a human leukocyte antigen (HLA)-identical relative or HLA-matched unrelated donor. We studied cumulative incidence of relapse (CIR) and survival prediction accuracy using a NGS-based MRD-assay targeting immunoglobulin genes after 2 courses of consolidation chemotherapy cycles in 93 adults with B-cell ALL most receiving HLA-haplotype-matched related transplants. Prediction accuracy was compared with MRD-testing using multi-parameter flow cytometry (MPFC). NGS-based MRD-testing detected residual leukemia in 28 of 65 subjects with a negative MPFC-based MRD-test. In Cox regression multi-variable analyses subjects with a positive NGS-based MRD-test had a higher 3-year CIR (Hazard Ratio [HR] = 3.37; 95 % Confidence Interval [CI], 1.34-8.5; P = 0.01) and worse survival (HR = 4.87 [1.53-15.53]; P = 0.007). Some data suggest a lower CIR and better survival in NGS-MRD-test-positive transplant recipients but allocation to transplant was not random. Our data indicate MRD-testing by NGS is more accurate compared with testing by MPFC in adults with B-cell ALL in predicting CIR and survival. (Registered in the Beijing Municipal Health Bureau Registration N 2007-1007 and in the Chinese Clinical Trial Registry [ChiCTR-OCH-10000940 and ChiCTROPC-14005546]).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
- Jichenjunchuang Clinical Laboratory, Hangzhou, Zhejiang, China.
- Jichenjunchuang Clinical Laboratory, Hangzhou, Zhejiang, China; Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 31…
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- NIHR Oxford Biomedical Research Centre
- National Institute for Health and Care Research
- Peking University People's Hospital
- Peking University
Zitieren
APA
Yan, N., Wang, Z. L., Wang, X. J., Gale, R. P., Zhou, Y. L., Zhao, M. Y., Wu, L. X., Liao, M. Y., Yang, J., Wang, C. Y., Zhu, J. H., Jiang, H., Jiang, Q., Liu, Y. R., Chang, Y. J., Xu, L. P., Zhang, X. H., Ma, T. H., Huang, X. J., & Ruan, G. R. (2024). Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217104
Vancouver
Yan N, Wang ZL, Wang XJ, Gale RP, Zhou YL, Zhao MY, et al. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217104
BibTeX
@article{Yan2024,
author = {Yan, Nan and Wang, Zi-Long and Wang, Xiao-Juan and Gale, Robert Peter and Zhou, Ya-Lan and Zhao, Ming-Yue and Wu, Li-Xin and Liao, Ming-Yue and Yang, Jie and Wang, Chun-Yang and Zhu, Jian-Hua and Jiang, Hao and Jiang, Qian and Liu, Yan-Rong and Chang, Ying-Jun and Xu, Lan-Ping and Zhang, Xiao-Hui and Ma, Tong-Hui and Huang, Xiao-Jun and Ruan, Guo-Rui},
title = {Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217104}
}
EUVIMED